Free tool
FAERS Monitor: Daptomycin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209949 or its brand name (Daptomycin, Daptomycin). Reports on generic versions are filed under their own applications.
Reports
9,502
Serious
8,805
93% of reports
Hospitalization
5,435
Death reported
1,286
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective768
- off label use703
- acute kidney injury628
- eosinophilic pneumonia487
- pyrexia481
- rhabdomyolysis389
- eosinophilia387
- drug reaction with eosinophilia and systemic symptoms344
- blood creatine phosphokinase increased329
- product use in unapproved indication321
- neutropenia302
- thrombocytopenia288
- rash282
- interstitial lung disease275
- pneumonitis265
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 21 |
| 2006 | 22 |
| 2007 | 23 |
| 2008 | 31 |
| 2009 | 78 |
| 2010 | 67 |
| 2011 | 87 |
| 2012 | 121 |
| 2013 | 117 |
| 2014 | 128 |
| 2015 | 319 |
| 2016 | 237 |
| 2017 | 307 |
| 2018 | 595 |
| 2019 | 491 |
| 2020 | 665 |
| 2021 | 836 |
| 2022 | 899 |
| 2023 | 1,100 |
| 2024 | 1,107 |
| 2025 | 1,182 |
| 2026 | 1,059 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,657 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eosinophilic pneumoniaSignal | 487 | 404.4 | 368.0 | 165,403 |
| eosinophiliaSignal | 387 | 50.0 | 45.3 | 18,129 |
| drug reaction with eosinophilia and systemic symptomsSignal | 344 | 30.0 | 27.0 | 9,491 |
| blood creatine phosphokinase increasedSignal | 329 | 25.6 | 23.0 | 7,669 |
| pneumonitisSignal | 265 | 21.7 | 19.3 | 5,179 |
| rhabdomyolysisSignal | 389 | 20.8 | 18.9 | 7,272 |
| interstitial lung diseaseSignal | 275 | 12.6 | 11.2 | 2,926 |
| acute kidney injurySignal | 628 | 9.1 | 8.5 | 4,545 |
| thrombocytopeniaSignal | 288 | 5.7 | 5.1 | 1,118 |
| neutropeniaSignal | 302 | 4.9 | 4.4 | 945 |
| pyrexiaSignal | 481 | 3.1 | 2.8 | 684 |
| product use in unapproved indicationSignal | 321 | 2.9 | 2.6 | 393 |
| off label use | 703 | 1.8 | 1.7 | 249 |
| rash | 282 | 1.4 | 1.3 | 37 |
| drug ineffective | 768 | 1.3 | 1.2 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.